Michael Kappelman, MD, MPH, was the lead PI on the clinical trial, which followed nearly 300 children with Crohn’s to evaluate how their conditions changed in response to anti-TNF biologic treatments alone or in combination with a second immune suppressive medication.

A four-year clinical trial led by Edwin Kim, MD, at the UNC School of Medicine, has found that an increased dosage of a unique type of peanut allergy immunotherapy continues to show promise for children.

A new glioblastoma treatment from Northwest Biotherapeutics improved outcomes for many patients in a phase 3 clinical study, according to a study published in JAMA Oncology. Matt Ewend, MD, in the UNC Department of Neurosurgery and at UNC Lineberger, led the trial site at the N.C. Basnight Cancer Hospital.

This study, called IMPACT, was co-led by A. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine. Edwin Kim, MD, is co-author on the paper and leads peanut allergy research at the UNC School of Medicine.

James F. Howard Jr., MD, professor in the UNC Department of Neurology, was principal investigator of the phase 3 trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.

As part of the NIH-sponsored ACTIV-2 clinical trial for COVID-19 outpatients, preliminary data revealed that a new combination monoclonal antibody treatment reduced hospitalizations and death by 78 percent in high-risk patients. ACTIV-2 vice chair David Wohl, MD, leads monoclonal treatment for UNC Health.

Project Alive, a non-profit organization dedicated to finding a cure for Hunter syndrome, has surpassed its goal of raising $2.5 million dollars for a gene therapy clinical trial to be led by UNC School of Medicine researcher Joseph Muenzer, MD, PhD.

The first investigational agent to be evaluated by ACTIV-2 is LY3819253, an experimental monoclonal antibody treatment made by Lilly Research Laboratories in partnership with AbCellera Biologics.

UNC School of Medicine researchers led by Edwin Kim, MD, show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.

ZULRESSO, developed by Sage Therapeutics, is the first and only treatment specifically indicated to treat postpartum depression in women. UNC School of Medicine’s Samantha Meltzer-Brody, MD, MPH, was the principal investigator for three clinical trials showing rapid-reduction in depressive symptoms, and says the approval marks a major step forward in women’s healthcare.

Jessica Riley, a patient in the UNC Wound Healing Center took part in a clinical trial for venous leg ulcers

Patient Jessica Riley was referred to the UNC Wound Healing Center, part of the UNC Center for Heart and Vascular Care, for her venous leg ulcer and entered a clinical trial led by William Marston, MD **Graphic images included**

Tag: Clinical Trials

Researchers Announce Findings from Landmark Clinical Trial for Pediatric Crohn’s Disease

Novel Peanut Allergy Treatment Shown to be Safe, Effective, and Lasting

Ewend Leads UNC Hospitals Site for Successful National Glioblastoma Clinical Trial

Oral Immunotherapy Alleviates Peanut Allergy in Some Young Children

FDA Approves New Drug to Treat Generalized Myasthenia Gravis

Experimental Monoclonal Antibody Combo Shows Significant Efficacy against COVID-19

Community Rallies to Raise $2.5 Million for Gene Therapy Trial at UNC

Wohl launches clinical trial, one of 25 sites nationally testing COVID-19 treatments

New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and Safety

FDA Approves ZULRESSO™ (brexanolone) Injection for Postpartum Depression Following Three Clinical Trials Led by UNC Researcher

After suffering from open wound for almost two years, patient in UNC Center for Heart and Vascular heals in a matter of weeks as participant in clinical trial